SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.730
-0.090 (-2.36%)
Jul 13, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
285.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSABS News
- 6 days ago - Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - GlobeNewsWire
- 19 days ago - SAB Biotherapeutics initiated with an Overweight at Barclays - TheFly
- 6 weeks ago - SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - GlobeNewsWire
- 7 weeks ago - SAB Biotherapeutics initiated with a Buy at Citi - TheFly
- 7 weeks ago - SAB Biotherapeutics initiated with a Buy at Jefferies - TheFly
- 2 months ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 2 months ago - SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright - TheFly
- 2 months ago - SAB Biotherapeutics Earnings Call Transcript: Q1 2026 - Transcripts